In the current therapeutic landscape, immune checkpoint inhibitors (ICIs) targeting PD-1 and CTLA-4, as well as targeted therapies against MAPK pathway components (e.g., BRAF and MEK inhibitors), have become standard-of-care treatments in melanoma. The gene discussed is BRAF; the disease is melanoma.